To include your compound in the COVID-19 Resource Center, submit it here.

Merckle's ML3000 fails another Phase III

Merckle (Blaubeuren, Germany) said its Licofelone (ML3000) missed the primary endpoint of showing

Read the full 136 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE